35290-97-2

Usage

Uses

Used in Pharmaceutical Industry:
4-AMINO-5-BROMO-2-METHOXYBENZENECARBOXYLIC ACID is used as an impurity in the synthesis of bromopride (B686645), which is an antiemetic agent. It plays a crucial role in the development and production of medications aimed at treating nausea and vomiting associated with various conditions, such as motion sickness, pregnancy, and chemotherapy.
In addition to its use in the pharmaceutical industry, 4-AMINO-5-BROMO-2-METHOXYBENZENECARBOXYLIC ACID may also have potential applications in other industries, such as chemical synthesis, material science, and research, due to its unique structural properties.

InChI:InChI=1/C8H8BrNO3/c1-13-7-3-6(10)5(9)2-4(7)8(11)12/h2-3H,10H2,1H3,(H,11,12)

Upstream product

• 4093-34-9 2-Methoxy-4-cetamino-5-brom-benzoesaeuremethylester 
• 27492-84-8 Methyl 4-amino-2-methoxybenzoate 
• 4136-97-4 methyl 4-aminosalicylate 
• 65-49-6 4-Aminosalicylic acid 
• 4093-28-1 methyl 4-acetamido-2-hydroxybenzoate 
• 4093-29-2 methyl 4-(acetylamino)-o-anisate 
• 111049-68-4 methyl 4-amino-5-bromo-2-methoxybenzenecarboxylate 

Downstream Products

• 286377-18-2 5-Bromo-2-methoxy-4-nitrobenzoic acid 
• 1240325-45-4 (4-amino-5-bromo-2-methoxyphenyl)-(1,3-dihydroisoindol-2-yl)methanone 
• 1388193-57-4 Br^(1-)*C₃₀H₃₂BrN₂O₇⁽¹⁺⁾ 
• 1388193-59-6 Br^(1-)*C₃₁H₃₄BrN₂O₇⁽¹⁺⁾ 
• 1388193-77-8 C₁₀H₁₁Br₂NO₃ 
• 1388193-79-0 C₁₁H₁₃Br₂NO₃ 
• 1441199-71-8 (5-bromo-2-methoxy-4-((4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)(morpholino)methanone 

Relevant academic research and scientific papers

ANTIVIRAL COMPOUNDS

Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).

Synthesis and biological evaluation of berberine derivatives as IBS modulator

Irritable bowel syndrome is the most common functional gastrointestinal disorder characterized by chronic abdominal pain or discomfort in association with a change in bowel habit. 5-HT receptor modulators have been developed as IBS therapeutic agents and proved to be effective in the treatment of the disease. In this letter, 12 berberine derivatives were designed and synthesized as 5-HT receptor modulators. Preliminary biological tests suggested that the new compounds exhibited promising activity for IBS therapy.

Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1- ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design

Inhibitors of the molecular chaperone heat shock protein 90 (Hsp90) are currently generating significant interest in clinical development as potential treatments for cancer. In a preceding publication (DOI: 10.1021/jm100059d) we describe Astex's approach to screening fragments against Hsp90 and the subsequent optimization of two hits into leads with inhibitory activities in the low nanomolar range. This paper describes the structure guided optimization of the 2,4-dihydroxybenzamide lead molecule 1 and details some of the drug discovery strategies employed in the identification of AT13387 (35), which has progressed through preclinical development and is currently being tested in man.

Bromopride: Metabolism and urinary elimination in dogs

The elimination of bromopride and its metabolites was studied in dogs. The drug was given by mouth in a single dose of 15 mg/kg or 45 mg/kg and assessed by thin-layer or gas chromatography. Bromopride and its metabolites are excreted mainly within the first 8 h after ingestion. Nine metabolites, above all the N-monodeethyl derivative, were encountered, while 10% of the drug was eliminated as such.